Unichem Laboratories Limited (UNICHEMLAB)

Loading page…

Unichem Laboratories Limited (UNICHEMLAB) · mywealthgrid

About

Unichem Laboratories is a mid-cap pharmaceutical company with a ₹3,803 Cr market cap. It operates a combined standalone and consolidated platform with quarterly revenue of ₹350–520 Cr and ₹315–633 Cr respectively, indicating diversification across product lines or geographies within Indian healthcare.

Founded: 1944
Face value: ₹2

Market cap

₹3,767 Cr

P/E

12.4×

P/B

1.4×

Dividend yield

ROE

9.8%

ROCE

4.5%

Debt / equity

0.17

OPM

8.4%

EPS (TTM)

₹43.3

Book value

₹386.0

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Profitability is highly volatile: standalone net profit ranged from −₹39.93 Cr (Sep 2025) to +₹264.29 Cr (Dec 2025), then fell to −₹15.39 Cr (Mar 2026). Verify whether these swings reflect one-time items or recurring operational issues.

Operating margin of 8.36% is structurally thin — verify whether this reflects cost pressures, competitive pricing, product mix, or cyclical conditions.

Consolidated revenue (avg ₹500–600 Cr/quarter) significantly exceeds standalone (avg ₹400–450 Cr/quarter), indicating material subsidiary or associate exposure — verify their composition, ownership, and margin profiles.

ROE of 9.78% suggests weak capital efficiency — verify cost of equity and whether returns are persistently below hurdle rates.

Generated analysis · source review pending

Growth drivers

Consolidated revenue base averaging ₹500–600 Cr per quarter (₹100–150 Cr above standalone) indicates significant subsidiary or associate platform — verify revenue and profit contribution by segment.

Jun 2026 consolidated OPM improved to 11.06% and net profit to ₹41.47 Cr, reversing prior losses — verify whether this operational improvement continues.

Debt-to-equity of 0.17 provides balance-sheet capacity for reinvestment or M&A — verify capex and acquisition pipeline.

Generated analysis · source review pending

2,528 historical price candles were omitted because the exchange source has not been verified.

₹535.1-5.9%1Y

Quick read

rule-based

Pros

+Profit CAGR of 49.1% over the last 5 years
+High promoter holding of 70.2% with no pledge

Cons

−Low return on equity of 4.2% (3-yr avg)

Research score

Structured signal from quality, growth, valuation and momentum.

62/100

Business quality: 28
Growth: 78
Valuation: 80

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	1,211	1,235	1,270	1,343	1,705	2,111	2,202
COGS	387	379	416	551	665	864	1,021
Gross profit	824	856	854	792	1,040	1,247	1,181
	874	765	782	838	940	982	997
	-50	91	72	-46	100	265	184
OPM %	-4.1%	7.4%	5.7%	-3.4%	5.9%	12.6%	8.4%
Depreciation	82	84	91	113	113	125	125
Interest	8	5	6	17	23	21	32
	91	50	48	-0	-26	35	265
Profit before tax	-48	51	22	-176	-62	155	292
Tax	12	17	-11	26	9	17	40
Tax %	24.8%	33.3%	-50.5%	14.7%	14.3%	11%	13.5%
	-60	34	33	-202	-70	138	253
PAT margin %	-5%	2.8%	2.6%	-15.1%	-4.1%	6.5%	11.5%
EPS (₹)	-8.6	4.9	4.7	-28.7	-10	19.5	35.9
EPS adjusted (₹)	-8.6	4.9	4.7	-28.7	-10	19.5	35.9
	—	82%	85.1%	—	—	0%	—
Annual report	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	Annual report for Mar 2026

₹ Cr	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	18	14	14	14	14	14	14	14	14	14
Reserves	1,045	2,666	2,606	—	2,543	2,604	2,421	2,348	2,437	2,703
	98	0	0	—	119	349	297	219	430	469
	365	513	530	—	450	351	460	588	689	551
Total equity & liabilities	1,527	3,194	3,150	—	3,126	3,319	3,193	3,169	3,569	3,737
	487	574	806	861	880	990	1,257	1,196	1,300	1,213
CWIP	250	238	92	—	568	494	147	123	31	100
Investments	8	896	921	—	396	264	2	1	0	0
	781	1,485	1,330	—	1,282	1,571	1,787	1,849	2,239	2,425
Total assets	1,527	3,194	3,150	—	3,126	3,319	3,193	3,169	3,569	3,737

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	68.1%	69.3%	67.3%	59%	61%	59.1%	53.7%
EBITDA margin %	-4.2%	7.4%	5.7%	-3.4%	5.9%	12.6%	8.4%
EBIT margin %	-10.9%	0.5%	-1.4%	-11.8%	-0.8%	6.6%	2.7%
PAT margin %	-5%	2.8%	2.6%	-15.1%	-4.1%	6.5%	11.5%
Working capital
Receivable days	—	74	142	160	131	135	137
Inventory days	—	518	527	414	387	418	349
Payable days	—	202	161	193	164	170	128
NWC days	—	390	508	382	353	382	359
Leverage
Current ratio	—	2.72	2.98	2.48	2.39	2.05	2.48
Debt to EBITDA	—	1.31	4.8	—	2.19	1.62	2.55
Debt to equity	—	0.05	0.13	0.12	0.09	0.18	0.17
Interest coverage	-5.2	11.1	4.8	-7	0.8	8.4	3.9
Asset turnover	—	0.4	0.38	0.42	0.54	0.59	0.59
Return ratios
Return on assets %	—	1.1%	1%	-6.3%	-2.2%	3.9%	6.8%
Return on capital employed %	—	2.2%	1.1%	-4.5%	0.7%	7%	4.5%
Return on equity %	—	1.3%	1.3%	-8.3%	-3%	5.6%	9.3%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	70.21%	70.22%	70.22%	70.22%	70.22%	70.22%	70.22%	70.22%	70.22%	70.22%	70.22%	70.22%
	0.83%	0.84%	0.9%	0.89%	0.94%	1.06%	0.98%	0.98%	1%	0.99%	1%	0.9%
	10.32%	10.75%	11.27%	11.58%	11.67%	11.63%	11.32%	10.92%	10.75%	10.74%	10.63%	10.46%
	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	18.64%	18.19%	17.61%	17.31%	17.17%	17.09%	17.48%	17.88%	18.03%	18.05%	18.15%	18.42%
No. of shareholders	—	—	—	—	—	—	—	—	23,577	23,267	23,386	25,347

Promoter holding up 0.01 percentage points since Sep 2023.

19 deals · 2 Aug 2023 – 9 Jul 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
9 Jul 2026	POLUNIN EMERGING MARKETS SMALL CAP FUND LLC	Bulk	NSE	Buy	6,00,901	₹646.44	₹38.84 Cr
11 Jun 2026	NK SECURITIES RESEARCH PRIVATE LIMITED	Bulk	NSE	Sell	10,63,012	₹486.94	₹51.76 Cr
11 Jun 2026	NK SECURITIES RESEARCH PRIVATE LIMITED	Bulk	NSE	Buy	10,63,012	₹486.70	₹51.74 Cr
11 Jun 2026	JUNOMONETA FINSOL PRIVATE LIMITED	Bulk	NSE	Sell	9,23,655	₹488.31	₹45.10 Cr
11 Jun 2026	JUNOMONETA FINSOL PRIVATE LIMITED	Bulk	NSE	Buy	9,16,676	₹487.89	₹44.72 Cr
11 Jun 2026	MICROCURVES TRADING PRIVATE LIMITED	Bulk	NSE	Sell	8,64,382	₹489.48	₹42.31 Cr
11 Jun 2026	MICROCURVES TRADING PRIVATE LIMITED	Bulk	NSE	Buy	8,64,382	₹489.27	₹42.29 Cr
11 Jun 2026	IRAGE BROKING SERVICES LLP	Bulk	NSE	Sell	7,58,636	₹487.66	₹37.00 Cr
11 Jun 2026	IRAGE BROKING SERVICES LLP	Bulk	NSE	Buy	7,09,993	₹485.58	₹34.48 Cr
11 Jun 2026	ELIXIR WEALTH MANAGEMENT PRIVATE LIMITED	Bulk	NSE	Buy	6,15,503	₹488.36	₹30.06 Cr

1–10 of 19

1 / 2

Mr. Mody Prakash AmrutNon-Executive - Non Independent Director-Chairperson related to Promoter
Mr. Pranay GodhaNon-Executive - Non Independent Director
Mr. Pabitrakumar Kalipada BhattacharyyaExecutive Director-CEO-MD
Mr. Arun Lalchand TodarwalNon-Executive - Independent Director
Mr. Anand Trimbak KurseNon-Executive - Independent Director
Mrs. Swati Arvind PatankarNon-Executive - Independent Director
Mr. Sanjay JainChief Financial Officer
Mr. Pradeep BhandariCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

across 2 fund houses

Held by these funds

1.6%

of the company's equity

All mutual funds

9.32%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

3 schemes · 2 fund houses

		Shares
Healthcare Fund	DSP Mutual Fund	11.29 L	62.82	1.64%	1.603%	+4,171
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	560	0.03	0.07%	0.001%	+1
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	61	0	0.01%	0%	-0

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Credit ratings

Announcement under Regulation 30 (LODR) - Credit Rating10 Apr 2026

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

18 announcementsExport CSV

19 Sept 2026, 11:34 amCompany Update

Disclosure Under Regulation 30 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015

General PDF

Loading announcements…

Ratio	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	68.1%	69.3%	67.3%	59%	61%	59.1%	53.7%
EBITDA margin %	-4.2%	7.4%	5.7%	-3.4%	5.9%	12.6%	8.4%
EBIT margin %	-10.9%	0.5%	-1.4%	-11.8%	-0.8%	6.6%	2.7%
PAT margin %	-5%	2.8%	2.6%	-15.1%	-4.1%	6.5%	11.5%
Working capital
Receivable days	—	74	142	160	131	135	137
Inventory days	—	518	527	414	387	418	349
Payable days	—	202	161	193	164	170	128
NWC days	—	390	508	382	353	382	359
Leverage
Current ratio	—	2.72	2.98	2.48	2.39	2.05	2.48
Debt to EBITDA	—	1.31	4.8	—	2.19	1.62	2.55
Debt to equity	—	0.05	0.13	0.12	0.09	0.18	0.17
Interest coverage	-5.2	11.1	4.8	-7	0.8	8.4	3.9
Asset turnover	—	0.4	0.38	0.42	0.54	0.59	0.59
Return ratios
Return on assets %	—	1.1%	1%	-6.3%	-2.2%	3.9%	6.8%
Return on capital employed %	—	2.2%	1.1%	-4.5%	0.7%	7%	4.5%
Return on equity %	—	1.3%	1.3%	-8.3%	-3%	5.6%	9.3%

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Date	Category	Subject	Filing
19 Sept 2026, 11:34 am	Company Update General	Disclosure Under Regulation 30 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015	PDF
11 Sept 2026, 3:30 pm	Company Update General	Extension Of The Exercise Period For The Options Granted And Vested Under Unichem Employee Stock Option Scheme 2018	PDF
26 Aug 2026, 3:40 pm	Company Update General	Significant Increase In The Volume Of Securities.	PDF
26 Aug 2026, 2:03 pm	Company Update Clarification	Clarification sought from Unichem Laboratories Ltd	—
11 Aug 2026, 4:47 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Outcome of AGM	PDF
11 Aug 2026, 1:54 pm	Result Financial Results	Q1 Financial Statement Of FY 2026-2027	PDF
11 Aug 2026, 1:49 pm	Board Meeting Outcome of Board Meeting	Board Meeting Outcome for Outcome Of Board Meeting	PDF
29 Jul 2026, 1:00 pm	Company Update General	Disclosure Under Regulation 30 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015	PDF

₹ Cr	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	68	-112	-328	20	33	-260	-85	17	-7	4
	-128	1,648	-286	-36	-74	100	203	50	-241	192
	59	-881	-2	-62	-121	191	-81	-106	184	2
Net cash flow	-0	655	-616	-78	-162	32	36	-39	-64	198
Free cash flow	-82	-272	-522	-366	-255	-387	-129	-6	-144	-119
CFO / Operating profit %	—	—	—	—	36.3%	-356.6%	—	16.7%	-2.7%	2%

Unichem Laboratories Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Credit ratings

Events

Announcements

Not in the F&O segment

Announcements

Annual reports

Credit ratings

19

1

1

Compounded sales growth

Compounded profit growth

Return on equity

Unichem Laboratories Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Credit ratings

Events

Announcements

Not in the F&O segment

Ratio timeline

Announcements

Annual reports

Credit ratings

Quarterly record

Bulk & block deals

Board and management

Dividends19

Board meetings1

Stock splits1

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

19

1

1